Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial

The trial tested six injectable doses and three oral doses over as long as 36 weeks

Novo Nordisk’s Semaglutide fails to slow Alzheimer’s progression in Phase 3 trials

The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years

Abbott issues urgent correction for FreeStyle Libre 3 Sensors amid safety concerns

Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)

Alzheimer’s testing goes painless, homebound with Neurogen-Tasso partnership

The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating

Abbott to acquire Exact Sciences for $21 billion

Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology

Zydus receives FDA’s final approval for Verapamil Hydrochloride ER tablets

Contineum MS drug stumbles in mid-stage trial

Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints

Aptus Pharma enters into urology therapy segment

The company will soon be launching a new portfolio of products in this segment

FDA investigates fatal case linked to rare blood disorder drug Adzynma

Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme

Bayer’s experimental stroke drug could reshape secondary stroke prevention

Millions of stroke survivors across the world may soon have a new defense